Avoiding the health risks from the cold and snow
Staying healthy during the winter
Study links e-cigs to formaldehyde, cancer risk
Formaldehyde in e-cigs?
Time-restricted eating for better health?
Your eating clock
Is pet insurance worth it?
The real costs of pet insurance
Does Charles Payne think he’s smarter because he stays up late?
Night owl = Genius?
Analysis: For Merck, bringing cattle feed Zilmax back won't be easy
U.S. pharmaceutical giant Merck & Co faces significant challenges bringing its controversial feed additive Zilmax back to market in the United States and Canada, even after a vote of confidence from South Korea on Thursday.
Royalty Pharma Drops Hostile Bid for Elan
Royalty Pharma's $8 billion bid for the Irish drug firm lapsed when it withdrew an appeal against a ruling by Ireland's regulator on takeover bids.
AstraZeneca to Pay Up to $1.15B for Pearl Therapeutics
The biopharmaceutical business is buying privately-held Pearl Therapeutics for up to $1.15 billion to build its portfolio of respiratory disease drugs.
AstraZeneca to Pay Up to $1.15B for Pearl Therapeutics
The biopharmaceutical business is buying privately-held Pearl Therapeutics for up to $1.15 billion to build its portfolio of respiratory disease drugs.
WSJ: P&G to Regroup Products into 4 Sectors
The company is reportedly working to regroup its products and brands into four sectors, each led by a president reporting to the chief executive.
AstraZeneca Buys Omthera for $323M, Expands Fleet of Cholesterol Fighters
The global biopharmaceutical business has entered into a definitive agreement to buy Omthera Pharmaceuticals in a deal valued at $323 million.
AstraZeneca Buys Omthera for $323M, Expands Fleet of Cholesterol Fighters
The global biopharmaceutical business has entered into a definitive agreement to buy Omthera Pharmaceuticals in a deal valued at $323 million.
Merck Signs $5B Share Buyback Agreement with Goldman Sachs
The drug giant is looking to prop up shareholder value in face of stiff competition from makers of less-costly generics.
Glencore Xstrata Chairman Ousted in Surprise Coup
John Bond surprised investors by announcing he had been voted out of the top job at the group's first annual shareholders' meeting.
Humana 1Q Profit Soars 91% on Lower Benefit Costs, Raises Outlook
The health-care company reported a a stronger-than-expected increase in profit as membership grew and raised its full-year outlook.
Humana 1Q Profit Soars 91% on Lower Benefit Costs, Raises Outlook
The health-care company reported a a stronger-than-expected increase in profit as membership grew and raised its full-year outlook.
Pfizer Slumps on 1Q Miss, Outlook Downgrade
Shares of the drugmaker dropped after it reported lower-than-expected quarterly earnings and revenue and trimmed its full-year profit outlook.
Bayer Shells Out $1.1B to Buy Contraceptive Maker Conceptus
The German company plans to acquire Conceptus for $1.1 billion in cash.
Medical Care Slowdown Hits Companies
With the start of the health-care overhaul looming, medical companies have been hurt by Americans making even fewer trips to the doctor's office.
SAC's Martoma switches lawyers in insider-trading case
Mathew Martoma, a former portfolio manager at hedge fund SAC Capital Management, has hired a new lawyer to defend him in his insider-trading case.